Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Inviragen presents DENVax Phase 1 trial results on dengue at ASTMH annual meeting

Inviragen, Inc. presented results of the Phase 1 clinical trial of DENVax conducted in Colombia at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting today.

8 Dec 2011

Influenza shot boosts immune response in pregnant women, protects neonatal babies

The researchers studied the immune response of 107 pregnant women after they were injected with a single dose of non-adjuvant H1N1 vaccine. They concluded that the influenza shot boosted the immune response in pregnant women and at the same time protected neuronatal babies via the antibodies that transferred through the placenta.

8 Dec 2011

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced results from CLEOPATRA, the first randomized Phase III study of the investigational HER2-targeted medicine pertuzumab.

8 Dec 2011

Vaccine against Ebola developed

Ebola was first identified in 1976 in Sudan and Zaire, which is now the Democratic Republic of the Congo and Ebola fever kills more than 90% of the people it infects. Ebola is among the most lethal diseases known to humans, according to the World Health Organization.

7 Dec 2011

MorphoSys unveils next-generation antibody technology Ylanthia

MorphoSys AG today unveiled its next-generation antibody technology Ylanthia®. The technology was presented to an audience of specialists at the 2011 Antibody Engineering and Antibody Therapeutics Conference in San Diego. MorphoSys expects Ylanthia to set new standards for therapeutic antibody generation in the pharmaceutical industry over the next decade and beyond. Commercial application will commence in 2012.

6 Dec 2011

HRF inhibitors may provide new therapeutic avenue for treatment of asthma and allergies

La Jolla Institute for Allergy & Immunology scientists have identified the histamine releasing factor (HRF) molecule as a promising target for developing new treatments for a number of allergic reactions including asthma.

3 Dec 2011

New rapid blood test for early diagnosis of cryptococcosis

Research conducted at University of Nevada, Reno and licensed through the University's Technology Transfer Office is featured in the technology transfer publication "Better World Report" for a remarkable second year in a row.

3 Dec 2011

Researchers identify critical steps leading to myelin destruction in neuromyelitis optica

Mayo Clinic researchers have identified critical steps leading to myelin destruction in neuromyelitis optica (NMO), a debilitating neurological disease that is commonly misdiagnosed as multiple sclerosis (MS). The findings could lead to better care for the thousands of patients around the world with NMO. The paper was published in the journal, Proceedings of the National Academy of Sciences, USA.

3 Dec 2011

AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

AVEO Pharmaceuticals, Inc. and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO's novel HGF inhibitory antibody that is currently in Phase 2 clinical development in patients with non-small cell lung cancer.

2 Dec 2011

Positive interim data from Anthera's PEARL-SC phase 2b clinical study in systemic lupus erythematosus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced positive interim biomarker data from the PEARL-SC phase 2b clinical study in patients with systemic lupus erythematosus.

1 Dec 2011

Celldex launches rindopepimut Phase 3 trial in EGFRvIII-positive glioblastoma

Celldex Therapeutics, Inc. today announced that it has launched a pivotal, randomized, double-blind, controlled Phase 3 trial of rindopepimut in patients with surgically resected epidermal growth factor variant III (EGFRvIII)-positive glioblastoma, the "ACT IV Study."

1 Dec 2011

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Speaking today at the plenary session of the 7th Annual European Antibody Congress in Geneva, Dr. Anat Cohen-Dayag, President and CEO of Compugen Ltd., presented Compugen's Antibody Target Discovery Platform, one of the Company's predictive discovery platforms for novel therapeutic targets.

1 Dec 2011

arGEN-X closes EUR 27.5 million Series B fundraising round

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announced today the closing of a EUR 27.5 million (USD 37 million) Series B fundraising round, which was oversubscribed.

1 Dec 2011

Neogenix novel antibody selected as one of Windhover's 2011 Top 10 Projects to Watch

Neogenix Oncology, Inc. has announced that the company's novel antibody NEO-101, which targets pancreatic and colorectal cancer cells, has been selected as one of Windhover's 2011 Top 10 Projects to Watch.

30 Nov 2011

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

Genentech, a member of the Roche Group, today announced the company will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium December 6-10.

30 Nov 2011

Leica Microsystems announces availability of ChromoPlex 1 Dual Detection for BOND

Leica Microsystems announced today the availability of Leica ChromoPlex 1 Dual Detection for BOND, the first fully automated one-step detection system allowing the co-visualization of mouse and rabbit antibodies on a single slide.

28 Nov 2011

Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia

Micromet, Inc. today announced that it has initiated a phase 2 trial of its lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

28 Nov 2011

Randox expand range of immunoturbidimetric proteins

With the recent launch of the Haptoglobin and Ceruloplasmin assays Randox now have one of the largest ranges of immunoturbidimetric proteins on the market. All reagents are liquid ready to use for added convenience; furthermore, automated applications are available for most chemistry systems eliminating the need for specialised protein analysers.

From Randox Laboratories Ltd. 24 Nov 2011

NIH-led study advances HIV vaccine research

HIV is coated in sugars that usually hide the virus from the immune system. Newly published research reveals how one broadly neutralizing HIV antibody actually uses part of the sugary cloak to help bind to the virus. The antibody binding site, called the V1/V2 region, represents a suitable HIV vaccine target, according to the scientists who conducted the study. In addition, their research reveals the detailed structure of the V1/V2 region, the last part of the virus surface to be visualized at the atomic level.

24 Nov 2011

USPTO issues patent to BioFactura's StableFast platform

BioFactura, Inc. was awarded a US patent covering the core technologies of its proprietary StableFast Biomanufacturing Platform. The US Patent and Trademark Office allowed 32 claims broadly covering composition of matter, methods, commercial kits, and media formulations.

23 Nov 2011

Antibody News and Research

Further Reading

Inviragen presents DENVax Phase 1 trial results on dengue at ASTMH annual meeting

Influenza shot boosts immune response in pregnant women, protects neonatal babies

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

Vaccine against Ebola developed

MorphoSys unveils next-generation antibody technology Ylanthia

HRF inhibitors may provide new therapeutic avenue for treatment of asthma and allergies

New rapid blood test for early diagnosis of cryptococcosis

Researchers identify critical steps leading to myelin destruction in neuromyelitis optica

AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

Positive interim data from Anthera's PEARL-SC phase 2b clinical study in systemic lupus erythematosus

Celldex launches rindopepimut Phase 3 trial in EGFRvIII-positive glioblastoma

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

arGEN-X closes EUR 27.5 million Series B fundraising round

Neogenix novel antibody selected as one of Windhover's 2011 Top 10 Projects to Watch

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

Leica Microsystems announces availability of ChromoPlex 1 Dual Detection for BOND

Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia

Randox expand range of immunoturbidimetric proteins

NIH-led study advances HIV vaccine research

USPTO issues patent to BioFactura's StableFast platform

Using single B cell screening to boost antibody discovery eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo